Companies with novel uses for menstrual blood samples (a biopsy that 25% of the world’s population give every month) and those looking for new ways to treat dysmenorrhea that affects up to 90% of menstruating women.

However, if we look at the total market, we see that out of the 4 biggest funding rounds in Femtech, 3 were raised by companies founded and built by men (Nurx, Hims/Hers, Ro/Rory). In fact, two of these four were initially men’s health companies, primarily selling on-demand pharma products, that then launched women-centered verticals (Hims/Hers, Ro... See more

Over 60 million women in the US alone are menopausal however menopause (an inevitable part of female ageing) is still viewed by some as ‘niche’.